Comparing dopamine D2 receptor occupancies for use in clinical practice: Attractive proposition but fraught with pitfalls

Journal of Clinical Psychopharmacology

Volumn 34, Issue 4, 2014, Pages 530-532

  Lee, Jimmy ^a,b,c,d   Takeuchi, Hiroyoshi ^c,d,e   Remington, Gary ^c,d  

^a INSTITUTE OF MENTAL HEALTH   (Singapore)

^b DUKE NUS MEDICAL SCHOOL   (Singapore)

^c CENTRE FOR ADDICTION AND MENTAL HEALTH   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; DOPAMINE 2 RECEPTOR; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT;

CLINICAL PRACTICE; DOSE CALCULATION; DOSE RESPONSE; LETTER; POSITRON EMISSION TOMOGRAPHY; PRESCRIPTION; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RECEPTOR OCCUPANCY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THERAPEUTIC EQUIVALENCE; BRAIN; DRUG EFFECTS; FEMALE; HUMAN; MALE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BRAIN; DOPAMINE ANTAGONISTS; DOPAMINE D2 RECEPTOR ANTAGONISTS; FEMALE; HUMANS; MALE; SCHIZOPHRENIA;

EID: 84903729622     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0000000000000149     Document Type: Letter

References (13)

1. Lako IM, van den Heuvel ER, Knegtering H, et al. Estimating dopamine D2 receptor occupancy for doses of 8 antipsychotics: a meta-analysis. J Clin Psychopharmacol. 2013;33:675-681.
2. Davis JM, Chen N. Dose response and dose equivalence of antipsychotics. J Clin Psychopharmacol. 2004;24(2):192-208. (Pubitemid 38380844)
3. Kane JM, Leucht S, Carpenter D, et al. The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry. 2003;64(suppl 12):5-19.
4. Gardner DM, Murphy AL, O'Donnell H, et al. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167(6):686-693.
5. Patel MX, Arista IA, Taylor M, et al. How to compare doses of different antipsychotics: a systematic review of methods. Schizophr Res. 2013; 149(1-3):141-148.
6. Yilmaz Z, Zai CC, Hwang R, et al. Antipsychotics, dopamine D2 receptor occupancy and clinical improvement in schizophrenia: a meta-analysis. Schizophr Res. 2012;140(1-3): 214-220.
7. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry. 2000;157(4):514-520. (Pubitemid 30191189)
8. Kapur S, Seeman P. Antipsychotic agents differ in how fast they come off the dopamine D2 receptors. Implications for atypical antipsychotic action. J Psychiatry Neurosci. 2000;25(2):161-166. (Pubitemid 30233553)
9. Kapur S, Zipursky R, Jones C, et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57(6):553-559. (Pubitemid 30349435)
10. Suhara T, Okauchi T, Sudo Y, et al. Clozapine can induce high dopamine D(2) receptor occupancy in vivo. Psychopharmacology (Berl). 2002;160(1):107-112. (Pubitemid 34169832)
11. Uchida H, Takeuchi H, Graff-Guerrero A, et al. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31(4):497-502.
12. Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther. 2002;302(1):381-389. (Pubitemid 34680462)
13. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156(2):286-293. (Pubitemid 29077120)